Cathie Wood Pours $24M Into Figma Stock While Dumping DraftKings for Second Day Running

TLDR

• ARK Invest bought ~$24M in Figma after strong Q4 earnings and a 6.9% stock surge
• ARK sold ~$10.8M of DraftKings for the second day running
• Compass Pathways picked up for ~$6.5M after a share price dip
• Recursion Pharmaceuticals bought for ~$2.9M despite Nvidia fully exiting its position
• Pinterest sold for ~$2.66M following weak Q4 results and a soft outlook

---

Cathie Wood’s ARK Invest made a string of trades on February 19, 2026, with Figma taking the top spot as the firm’s biggest buy of the day.

ARK purchased 964,342 shares of Figma for roughly $24 million, mostly through its ARKK ETF. Figma’s stock closed up 6.9% on the same day.

Figma, Inc., FIG

The design software company had just reported Q4 results that beat both sales and earnings estimates. CEO Dylan Field also addressed concerns that generative AI could hurt traditional software companies, arguing Figma is using AI to grow its platform.

Figma’s “Make” tool lets users type prompts that AI models from Anthropic and Google convert into working app prototypes. From March, Figma will start charging for AI usage through monthly credit limits and pay-per-use pricing.

ARK Exits DraftKings and Pinterest

ARK sold 480,919 shares of DraftKings for about $10.8 million through its ARKK ETF. It was the second consecutive day ARK reduced its position in the sports betting platform.

ARK also sold 158,945 shares of Pinterest for $2.66 million. Pinterest had recently reported weak Q4 2025 results and issued a cautious outlook for the period ahead.

Biotech and Mental Health Picks Up Steam

ARK’s ARKG ETF bought 781,085 shares of Compass Pathways for around $6.5 million. The British mental health drug maker’s stock had dropped 2.3% after announcing a 17.5 million share secondary offering priced at $8 per share.

ARK also added 780,532 shares of Recursion Pharmaceuticals for about $2.9 million. Recursion’s stock had risen 5.4% that day, bouncing back after Nvidia revealed it had fully exited its position in the AI-focused drug company during Q4.

ARK bought 28,055 shares of CRISPR Therapeutics for $1.5 million and 56,507 shares of Klarna for just over $1 million.

On the sell side, ARK offloaded 34,993 shares of Veeva Systems for $6.3 million and 31,523 shares of Twist Bioscience for $1.7 million.

Figma recorded the largest single-day gain among all stocks involved in Thursday’s trades, closing up 6.9% on the day ARK made its purchase.

The post Cathie Wood Pours $24M Into Figma Stock While Dumping DraftKings for Second Day Running appeared first on Blockonomi.